29th week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120183480 | Oil-In-Water Emulsified Composition - The present invention is an oil-in-water emulsified composition and a sunscreen cosmetic characteristically comprising the following (a)-(j):
| 2012-07-19 |
20120183481 | HEPARANASE ACTIVITY INHIBITOR - A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): | 2012-07-19 |
20120183482 | MELANIN PRODUCTION INHIBITOR - There is provides a melanin production inhibitor which effectively inhibits melanin production, and a highly safe whitening cosmetic exhibiting an excellent whitening effect which inhibits ultraviolet ray-induced skin melanism. | 2012-07-19 |
20120183483 | COSMETIC COMPOSITION FOR KERATIN FIBERS - The present invention relates to a cosmetic composition for keratin fibers, such as a composition for coloring hair or a composition for reshaping hair, comprising: (a) at least one phosphoric surfactant; (b) at least one non-ionic surfactant, (c) at least one polyol; (d) at least one oil; and (e) at least one alkaline agent. It is preferable that the cosmetic composition further comprises at least one higher alcohol. The present invention is useful because it does not generate odor while maintaining a level of cosmetic performance as comparable to that of conventional cosmetic compositions. | 2012-07-19 |
20120183484 | CARRAGEENAN MIXTURES USEFUL AS COSMETIC INGREDIENTS AND HAIR STYLING GELS COMPRISING THEM - This invention provides a carrageenan mixture comprising about 60% to about 95% by weight of iota-carrageenans and about 5% to about 25% by weight of lambda-carrageenans, which is useful as an ingredient of a cosmetic formulation such as a fully natural hair styling gel being free from synthetic polymers. | 2012-07-19 |
20120183485 | Compositions and method for thermal protection of hair - This invention details a method for providing thermal protection to human hair by applying an aerosolized polymer system to the hair before heat treatment. It has been found that acrylate polymers provide good protection from the damaging affects of curling irons and straightening irons and afford improvements in the look and feel of the treated hair. | 2012-07-19 |
20120183486 | Composition for Chemically Modifying the Internal Region of a Hair Shaft - A composition for chemically modifying the internal region of a hair shaft, wherein the composition comprises: an ethylenic monomer having a molecular weight of 500 g/mole or less; a cation and an anion; wherein the cation is selected from the group consisting of inorganic cations having a charge density of 0.05 charge/picometre or more; a cosmetically acceptable carrier; wherein the composition has a pH of from 4.0 to 6.9. | 2012-07-19 |
20120183487 | Novel Composition for Treating External Injuries and Eschars - The present invention relates to the use of a composition comprising 2-bromo-2-nitropropane-1,3-diol for external treatment of tissues of corpses. | 2012-07-19 |
20120183488 | COMPOSITIONS COMPRISING HYDROPHOBICALLY MODIFIED MALODOR CONTROL POLYMERS - Compositions comprising hydrophobically modified malodor control polymers and methods thereof are provided. In some embodiments, the composition comprises a malodor control polymer, a malodor counteractant comprising a perfume, an aqueous carrier, and a ph of about 6 to about 8. Such compositions may be used to reduce or neutralize malodors on surfaces or in the air. | 2012-07-19 |
20120183489 | COMPOSITIONS COMPRISING METALLATED MALODOR CONTROL POLYMERS - Compositions comprising a metallated malodor control polymer, a malodor counteractant comprising a perfume material, an aqueous carrier, and a pH of about 5 to about 10; and methods thereof are provided. Such compositions may be used to reduce or neutralize malodors on surfaces or in the air. | 2012-07-19 |
20120183490 | NOVEL 1,3-OXATHIANE COMPOUNDS AND THEIR USE IN FLAVOR AND FRAGRANCE COMPOSITIONS - The present invention relates to novel 1,3-oxathiane compounds represented by Formula I: | 2012-07-19 |
20120183491 | IODINE- AND AMYLOSE-CONTAINING FIBERS, METHOD FOR PRODUCTION THEREOF, AND USE THEREOF - A method for producing an amylose-containing rayon fiber, comprising the steps of: mixing an aqueous alkaline solution of amylose with viscose to obtain a mixed liquid, spinning the mixed liquid to obtain an amylose-containing rayon fiber, and bringing the amylose-containing rayon fiber into contact with iodine or polyiodide ions, thereby allowing an amylose in the amylose-containing rayon fiber to make a clathrate including the iodine or polyiodide ions, wherein the amylose is an enzymatically synthesized amylose having a weight average molecular weight of 3×10 | 2012-07-19 |
20120183492 | External Preparation For The Skin - An external preparation for skin has a pH value of 2.0-5.0 and comprises: (a) 1.0-7.0 mass % of at least one of the members selected from hydroxy acids, (b) 0-0.1-3.0 mass % of a crosslinked type N,N-dimethylacrylamide-2-acrylamido-2-methylpropane sulfonic acid sodium salt copolymer, and (c) 0-0.1-3.0 mass % of an associating thickener constituted of a compound of the formula (1): R | 2012-07-19 |
20120183493 | NOVEL POLYMERS - The present invention relates to polymers comprising monomer units derived from captopril, and their use in the treatment or prevention of collagen deposition, fibrosis, scars, burns, or unwanted tissue formation. The present invention further relates to processes for the preparation of said polymers and to pharmaceutical compositions and medical products comprising the polymers. Also encompassed by the present invention are polymers comprising monomer units derived from other ACE inhibitors such as zofenopril, alacepril, rentiapril or pivalopril, or from vasopeptidase inhibitors such as fasidotrilat, omapatrilat or ilepatril. | 2012-07-19 |
20120183494 | NOVEL N-HALAMINE ACRYLAMIDE MONOMERS AND COPOLYMERS THEREOF FOR BIOCIDAL COATINGS - Novel acrylamide and methacrylamide hydantoin monomers which can be reacted with other acrylamide, methacrylamide, acrylate, and methacrylate monomers to form copolymers, which upon halogenation, provide oxidative coatings which are biocidal for use with various materials including, but not limited to, textiles, filters, and latex paints. | 2012-07-19 |
20120183495 | AVIAN COLONY STIMULATING FACTOR 1 RECEPTOR BINDING PROTEINS - The present invention provides avian CSF1 genes encoding proteins which bind avian colony stimulating factor 1 receptor (CSF1R) and which exhibit immunomodulatory properties. | 2012-07-19 |
20120183496 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE - The present invention provides, among other things, compounds represented by the general Formula I: | 2012-07-19 |
20120183497 | Method of Determining Response to Treatment with Immunomodulatory Composition - The present invention provides a method for accurately determining the likelihood that a subject will respond to treatment with an immunomodulatory composition comprising detecting one or more markers in a sample from the subject, wherein at least one markers is linked to a single nucleotide polymorphism (SNP) set forth in Table 1 or 3-5, and processes for selecting suitable subjects for therapy or for continued therapy, and for providing appropriate therapy to subjects, based on the assay results. | 2012-07-19 |
20120183498 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES - Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection. | 2012-07-19 |
20120183499 | Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiopathic pulmonary fibrosis (IPF), mixed connective tissue disease and asthma, comprising administering an aerosolized interferon such as interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) alone or in combination with other therapeutic agents are provided. | 2012-07-19 |
20120183500 | ARTICLES AND METHODS INCLUDING STABLE THERMALLY-RESPONSIVE POLYMERS - Embodiments of the invention can include or be used in conjunction with implantable medical devices and various in vitro applications. In an embodiment, an implantable medical device is included herein. The device can include a frame having an inner lumen; the frame comprising a copolymer formed from monomers comprising N-isopropylacrylamide or a thermally responsive derivative thereof and a second monomeric species including one or more of a heteroatom or a charged moiety. In an embodiment, a method of isolating a component of a mixture is included herein. The method can include mixing a sample with a copolymer formed from monomers comprising N-isopropylacrylamide or a thermally responsive derivative thereof and a second monomeric species including one or more of a heteroatom or a charged moiety to form a reagent mixture, the copolymer further comprising a moiety exhibiting affinity for an analyte in the sample. The method can further include raising the temperature of the reagent mixture to high enough for the copolymer to form a hydrogel. Other embodiments are also included herein. | 2012-07-19 |
20120183501 | NOVEL METHOD FOR TREATMENT OF SKIN WOUNDS AND PREPARATIONS FOR IMPLEMENTATION OF SAME - Method for treatment of skin wounds, in a patient needing it, in which an effective amount of an insoluble globin preparation is placed in direct contact with the skin wound, the preparation is kept in place for at least one week, without having to change or wash the wound during said time and without a local infection, which would be detrimental to the patient. | 2012-07-19 |
20120183502 | COMBINATION THERAPY FOR LYSOSOMAL STORAGE DISEASES - This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases. | 2012-07-19 |
20120183503 | LACTOBACILLUS AND STREPTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from | 2012-07-19 |
20120183504 | COMPOSITION AND USE OF PROBIOTIC STRAIN GM-263 (ADR-1) IN TREATING RENAL FIBROSIS IN DIABETES - A use of probiotic strain GM-263 (ADR-1) in treating renal fibrosis in diabetes is disclosed. The probiotic strain such as | 2012-07-19 |
20120183505 | ARTIFICIAL DERMIS AND METHOD OF PREPARATION - Artificial dermis ( | 2012-07-19 |
20120183506 | PREVENTION AND TREATMENT OF ALLERGIC DIARRHOEA - This invention relates to | 2012-07-19 |
20120183507 | Non-Toxigenic Strains of Aspergillus Flavus for Control of Aflatoxin Contamination in Crops - Non-toxigenic strains of | 2012-07-19 |
20120183508 | GAMMA SECRETASE INHIBITOR FOR TREATMENT OF HERPESVIRUS INFECTION - This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention s relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby arresting the growth of the infected cells. | 2012-07-19 |
20120183509 | MICROGLIAL PRECURSOR CELLS FOR THE TREATMENT OF MALIGNANT NEOPLASMS OF THE CENTRAL NERVOUS SYSTEM - Microglial precursor cells for use in the treatment of malignant neoplasms of the central nervous system. A method of treating malignant neoplasms of the central nervous system comprising administering a pharmaceutically effective amount of microglial precursor cells to a subject in need thereof. | 2012-07-19 |
20120183510 | HIGH-THROUGHPUT CULTURE AND TRANSFER DEVICE AND METHOD - A method and device for creating hanging drop cell aggregates. The method and device includes a plurality of pegs that allow for high throughput culture of aggregates. Also disclosed are means of transferring formed aggregates to various destinations, such as well plates, scaffolding, tissues, or wounds. Use of the device permits aggregates to be prepared or created in larger quantities than current methods, and allows for them to be transferred more efficiently. | 2012-07-19 |
20120183511 | INDUCTION OF NEURONAL DIFFERENTIATION IN NON-NEURONAL CELLS USING A NUCLEIC ACID MOLECULE - A method of transdifferentiating a non-neuronal mammalian cell into a neuronal cell including transfecting the non-neuronal non-terminally differentiated mammalian cell with a nucleic acid that promotes the transdifferentiation of the cell into a neuronal cell, wherein the nucleic acid is substantially homologous to BORG RNA. | 2012-07-19 |
20120183512 | TCTEX-1 REGULATORY SEQUENCE AS STEM CELL MARKER - The disclosure relates to an isolated regulatory sequence for Tctex-1 that is transcriptionally active in adult neural progenitor and stem cells, including Type 1, Type 2 and Type 3 progenitors, as well as during development. The disclosure also relates to a method for selectively expressing a genetic sequence in neural progenitor cells. The disclosure of inserting and expressing a specific sequence in these cells allows marking, identification, sorting, tracking, and manipulating neural progenitor and stem cells. | 2012-07-19 |
20120183513 | Lactobacillus Supplement for Alleviating Type I Diabetes | 2012-07-19 |
20120183514 | INFANT CEREAL COMPRISING NON-REPLICATING PROBIOTIC MICROORGANISMS - The present invention relates to the field of infant cereals. In particular, the present invention relates to the field of infant cereals that can be used to strengthen the immune system of the infant and/or that can be used to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to an infant cereal comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms. | 2012-07-19 |
20120183515 | ORAL NUTRITIONAL SUPPLEMENT COMPRISING PROBIOTICS - The present invention relates to the field of nutrition. In particular, the present invention relates to the field of oral supplements. One embodiment of the present invention relates to the field of oral supplements comprising probiotics and/or bioactive non-replicating probiotics, for example heat treated probiotics. | 2012-07-19 |
20120183516 | Lactic acid bacteria and bifidobacteria for treating endotoxemia - The invention relates to use of a bacterium selected from a lactic acid bacterium, a | 2012-07-19 |
20120183517 | COMPOSITION TO OBTAIN A BIOLOGICAL FUNGICIDE AND BACTERICIDE WITHOUT THE USE OF ANTIBIOTICS TO CONTROL PLANT DISEASES ETC. - A composition used to obtain a biological fungicide and bactericide without the use of antibiotics to control plant diseases, consisting in native strains. The composition is characterized in that it includes strains of the bio-controllers | 2012-07-19 |
20120183518 | ASSAY FOR DETERMINING HEALTH OF CD8+ T CELLS - A method of determining if a subject's CD8+ T-cells functionally recognize an HLA-E/Hsp60sp target structure comprising a) contacting a sample of the subject's CD8+ T-cells with a HLA-E+ cell loaded with Hsp60sp, b) quantifying proliferation of the contacted HLA-E+ cell, c) contacting a sample of the subject's CD8+ T-cells with a HLA-E+ cell which is loaded with a peptide which does not bind to HLA-E, d) quantifying proliferation of the HLA-E+ cell loaded with the peptide which does not bind to HLA-E following contact with the subject's CD8+ T-cells, e) comparing the proliferation quantified in step d) with the proliferation quantified in step b) | 2012-07-19 |
20120183520 | MINIMALLY INVASIVE METHODS FOR TREATING DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of acute or chronic dysfunction of cardiac muscle. The method may employ a kit which includes a platelet-rich plasma composition and a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device means to obtain platelet-rich plasma. | 2012-07-19 |
20120183521 | EQUINE NUTRITIONAL SUPPLEMENT - A nutriceutical supplement for use in equines provides enhanced mitochondrial energizing activity and reduced inflammation and results in enhanced resistance to training injuries and diseases and enhances peak racing performance. The supplement is provided along with equine feed as a formulation including at least Coenzyme Q10, Carnitine, d-Ribose, Boswellia extract and Curcumin. These ingredients provide enhanced mitochondrial energizing activity and reduced stress, inflammation and injuries. | 2012-07-19 |
20120183522 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I: | 2012-07-19 |
20120183523 | Methods and Compounds for Promoting Vessel Regression - The present invention relates, at least in part, to methods and compositions for treating and diagnosing disorders associated with neovascularization, and methods for identifying targets and compositions used in treating and diagnosing such disorders. | 2012-07-19 |
20120183524 | MOLECULAR TARGETS FOR TREATMENT OF INFLAMMATION - Molecular targets and methods for treating inflammatory disorders are described. The expression and/or functionality of molecular targets RelB or SIRT1 is modified in order to treat inflammatory disorders. The expression of RelB or SIRT1 may be increased, or the activity of RelB or SIRT1 may be increased in order to inhibit transcription factors which activate genes involved in inflammation. Inflammatory disorders such as chronic obstructive pulmonary disorder, rheumatoid arthritis, asthma and idiopathic pulmonary fibrosis are indicated. | 2012-07-19 |
20120183525 | FIBRINOGENOLYTIC ENZYME TABFIBLYSIN OF HORSEFLY, TABANUS YAO, ENCODING GENE AND USE THEREOF - A horsefly protease tabfiblysin isolated from the salivary gland of the horsefly, Tabanus Yao, a gene encoding the protease and use thereof are disclosed by the present invention. It belongs to the technical field of biomedicine. The molecular weight of the horsefly protease tabfiblysin is 27145.5 Daltons. Its full-length sequence is composed of 255 amino acids. Its encoding sequence is composed of 768 nucleotides. The horsefly protease tabfiblysin can hydrolyze fibrinogen and inhibit the aggregation of blood platelet dramatically, and can be used for preparing the drug for treating thrombotic diseases. | 2012-07-19 |
20120183526 | COMPOSITION FOR PREVENTING OR TREATING LIVER TOXICITY COMPRISING GALGEUNTANG OR LACTIC ACID BACTERIA FERMENTED GALGEUNTANG - The present invention relates to lactic acid fermented Galgeuntang, and a composition comprising the said lactic acid bacteria fermented Galgeuntang or Galgeuntang as an active ingredient, more particularly, to lactic acid fermented Galgeuntang prepared by the steps of inoculating lactic acid bacteria to Galgeuntang, culturing thereof, and fermenting thereof, and a composition for preventing or treating liver toxicity comprising the said fermented Galgeuntang or Galgeuntang. The composition of the present invention has treatment effect on liver toxicity, so that it can be effectively used as a liver function recovering agent or health food for liver function recovery. | 2012-07-19 |
20120183527 | MEASUREMENT OF ANTI-AMYLOID ANTIBODIES IN HUMAN BLOOD - The present invention provides improved immunoaffinity methods for detecting high avidity anti-amyloid antibodies present in a biological sample. In other aspects, the present invention provides methods for diagnosing diseases associated with amyloid proteins. Also provided by the present invention are methods for identifying candidates likely to respond to treatment comprising administration of an immunoglobulin preparation. | 2012-07-19 |
20120183528 | PNMT AS A NOVEL MARKER FOR PROGENITOR CELLS - In certain aspects, the present invention provides methods and compositions relating to a Pnmt-positive progenitor cell. In certain aspects, the present invention relates to methods for isolating and transplanting the subject progenitor cells, and methods for treating diseases such as myocardiac injuries and neurodegenerative disorders. | 2012-07-19 |
20120183529 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas. | 2012-07-19 |
20120183530 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS - The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 2012-07-19 |
20120183531 | Methods for Inhibiting Yellow Color Formation in a Composition - The present invention is related to methods for preventing or retarding (i.e., inhibiting) yellow color or peroxide formation in a composition. The present invention is also related to methods of reducing or decreasing the amount of yellow color or peroxide in a composition. More specifically, the present invention relates to the use of an antioxidant, an oxygen scavenger, pH, a chelating agent, and/or at least two factors in the methods of the invention. The present invention is also related to methods for predicting the rate of yellow color or peroxide formation in a composition. | 2012-07-19 |
20120183532 | COMPOUNDS STIMULATING UNDESIRABLE CELLULAR ADHESION AND APPLICATIONS THEREOF - The invention relates to non-glycosylated proteins, based on the Kre9 protein of | 2012-07-19 |
20120183533 | MIMOTOPES OF HIV ENV - The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS). | 2012-07-19 |
20120183534 | METHODS, COMPOSITIONS AND APPARATUSES FOR FACILITATING REGENERATION - Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells. | 2012-07-19 |
20120183535 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2012-07-19 |
20120183536 | METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE TREATMENT OF CANCER - Provided herein is are methods of treating cancer in a human by administering CRF, optionally in combination with a second agent, such as an angiogenesis inhibitor. | 2012-07-19 |
20120183537 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER - According to the invention there is provided a compound of formula (I) wherein: A represents C(═N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(═N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CR | 2012-07-19 |
20120183538 | SPARC ANTISENSE COMPOSITIONS AND USES THEREOF - The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis. | 2012-07-19 |
20120183539 | Cancer Metastasis Inhibitor - The present inventors used a model of intrasplenically induced liver metastasis to determine whether or not NF-κB activation in the liver is involved in the onset of metastatic tumors. When IKKβ was deleted from both liver cells and hematopoietically-derived cells, the onset of tumors was reduced remarkably. Tumor cells activated neighboring bone marrow cells (Kupffer cells) and produced mitogens such as interleukin (IL)-6, and this promoted angiogenesis and growth of tumors. The mitogen production depended on NF-κB in hematopoietically-derived Kupffer cells. Furthermore, treatment with an anti-IL-6 receptor antibody decreased the degree of metastatic tumor development. That is, the present inventors showed that tumor metastasis depends on inflammation, and proinflammatory intervention that targets Kupffer cells is useful for chemical prevention of metastatic tumors. Furthermore, it was shown that inhibition of the IKKβ/NF-κB signal transduction pathway, in particular IL-6 inhibition, can be utilized for anti-metastasis agents. | 2012-07-19 |
20120183540 | METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 2012-07-19 |
20120183541 | HAIR GROWTH METHODS USING FGFR4 EXTRACELLULAR DOMAINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 2012-07-19 |
20120183542 | TREATING NEUROLOGICAL DISORDERS - Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented. | 2012-07-19 |
20120183543 | DIAGNOSTIC BIOMARKERS FOR FIBROTIC DISORDERS - The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10. | 2012-07-19 |
20120183544 | DIAGNOSIS AND TREATMENT OF NEUROECTODERMAL TUMORS - The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors. | 2012-07-19 |
20120183545 | CD20-Binding Polypeptide Compositions and Methods - A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51. | 2012-07-19 |
20120183546 | TREATMENT OF OVARIAN CANCER USING A SPECIFIC BINDING AGENT OF HUMAN ANGIOPOIETIN-2 IN COMBINATION WITH A TAXANE - Methods and compositions for treating ovarian cancer in a patient comprising administering a therapeutically effective amount of an Angiopoictin-2 inhibitor in combination with a taxane. | 2012-07-19 |
20120183547 | COMPOSITIONS AND METHODS COMPRISING VEGFR-2 AND VEGFR-3 ANTAGONISTS FOR THE TREATMENT OF METASTATIC DISEASE - The invention is directed to methods for inhibiting growth of tumor metastases in lymph nodes, lungs and other distant organ sites comprising administering one or more VEGFR-3 antagonist(s) and optionally one or more VEGFR-2 antagonist(s). | 2012-07-19 |
20120183548 | IL-27 Antagonists for Treating Inflammatory Diseases - Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA. | 2012-07-19 |
20120183549 | CHEMOKINE RECEPTOR BINDING POLYPEPTIDES - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 2012-07-19 |
20120183550 | Therapeutic Using a Bispecific Antibody - Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules. | 2012-07-19 |
20120183551 | NOVEL HUMAN P53 SPLICE VARIANT DISPLAYING DIFFERENTIAL TRANSCRIPTIONAL ACTIVITY - Novel human p53 splice variant displaying differential transcriptional activity Described is a nucleic acid molecule encoding a p53 variant characterized in that it is capable of transactivating the p21- and 14-3-3σ-promoter but not the mdm2-, bax- and PIG3-promoter. Preferably, in said p53 variant exon 7, exon 8 and/or exon 9 are partially or entirely deleted. Finally, means for inhibiting the activity of this p53 variant are described which are useful for the therapy of cancer. | 2012-07-19 |
20120183552 | KIDNEY DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney. | 2012-07-19 |
20120183553 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS - Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods. | 2012-07-19 |
20120183554 | Biomarker - Described are gastrointestinal cancer specific biomarkers comprising the nucleic acid sequence of the Engrailed-2 (EN2) gene or the amino acid sequence of the encoded EN2 protein. Also described are uses of the biomarkers in the treatment, diagnosis, monitoring and imaging of gastrointestinal cancer. | 2012-07-19 |
20120183555 | SERUM MARKERS ASSOCIATED WITH EARLY AND OTHER STAGES OF BREAST CANCER - Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers. | 2012-07-19 |
20120183556 | SUPPRESSANT FOR ATHEROSCLEROSIS - The objective of the present invention is to provide an agent which is useful for suppressing actual atherosclerosis and has few side-effects. The suppressant for atherosclerosis according to the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody binding to C-tail of HMGB1 as an active component. | 2012-07-19 |
20120183557 | HIV TAT-CD4 HYBRID MOLECULES AND METHODS OF USE THEREOF - Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides. | 2012-07-19 |
20120183558 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2012-07-19 |
20120183559 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of marine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or anti-VEGF antibodies and/or antibodies directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 2012-07-19 |
20120183560 | Monoclonal Antibodies - The present invention provides an isolated antibody that binds a fibrin or fibrinogen γC domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen γC domain, inhibits Mac-1 binding to the fibrin or fibrinogen γC domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided. | 2012-07-19 |
20120183561 | ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY - There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them. | 2012-07-19 |
20120183562 | SECRETED FXYD PROTEINS EXPRESSED IN RESPONSE TO EPITHELIAL TISSUE DAMAGE, AND USES THEREFOR - Secreted FXYD family proteins are expressed by intestinal mucosa and/or associated tissues to regulate cell production in intestinal crypts in response to tissue damage. Such tissue damage may arise from disease, exposure to injurious chemicals (e.g., due to poisoning, chemotherapy, chemical weapons), or exposure to injurious radiation (e.g., due to nuclear power accidents, radiological weapons, radiation therapy). Because these proteins are secreted in response to epithelial tissue damage, some of them are implicated in tissue repair response or an inflammatory response which prolongs or exacerbates the tissue damage. Examples of these proteins include FXYD 3, FXYD 4, and FXYD 5. Diagnostic methods based upon the role of the FXYD proteins in epithelial tissue damage are disclosed. Also provided are antibodies raised against the FXYD family proteins, a kit for detecting at least an epitope of a polypeptide, a method of producing an antibody raised against an epitope of a polypeptide, and a method of diagnosing damage to an epithelial tissue. | 2012-07-19 |
20120183563 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R | 2012-07-19 |
20120183564 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION - The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods. | 2012-07-19 |
20120183565 | FULLY HUMAN ANTIBODIES TO BTLA - The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders. | 2012-07-19 |
20120183566 | Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof - The present disclosure provides aldehyde-tagged immunoglobulin (Ig) polypeptides that can be converted by a formylglycine-generating enzyme to produce a 2-formylglycine (FGly)-modified Ig polypeptide. An FGly-modified Ig polypeptide can be covalently and site-specifically bound to a moiety of interest to provide an Ig conjugate. The disclosure also encompasses methods of production of such aldehyde-tagged Ig polypeptides, FGly-modified Ig polypeptides, and Ig conjugates, as well as methods of use of same. | 2012-07-19 |
20120183567 | PROCESS FOR PRODUCING WATER-SOLUBLE HYALURONIC ACID MODIFICATION - The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel. | 2012-07-19 |
20120183568 | BIOASSAY FOR THE EARLY DETECTION OF AUTOIMMUNE DISEASES - Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a biological sample that is not a tear sample from the mammal with an antibody that specifically binds to a first polypeptide selected from the group Ctss, Ctsh, Ctsr, Ctsw, Ctsz, Ifng, IL-6ra, IL-10, IL-10ra, IL-15, Tnfa, Apo-F, or Lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided. | 2012-07-19 |
20120183569 | RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE - The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions. | 2012-07-19 |
20120183570 | ANTIGEN COMPOSITIONS AND METHODS OF INHIBITING CAMPYLOBACTER JEJUNI BACTERIAL INFECTION AND USES OF THE ANTIGEN COMPOSITIONS - Methods and compositions for reducing the incidence of | 2012-07-19 |
20120183571 | USE OF ANTRODIA CAMPHORATA FOR TREATING GOUT - The present invention relates to the use of antrodia camphorata in the treatment of skin conditions, such as acne vulgaris, urticaria and eczema, allergic rhinitis, diabetes mellitus and its complications, cancer cachexia, hypercholesterolemia, gout in a subject in need of such treatment. The present invention is also directed to the use of antrodia camphorata in the prevention and treatment of oral cancer and arterial restenosis, in a subject in need of such prevention. The methods comprise the steps of: identifying a subject in need thereof, and administering to the subject a formulation comprising an effective amount of antrodia camphorata, whereby the symptoms in the subject are reduced or prevented. The composition can be a pharmaceutical composition or a nutraceutical composition. | 2012-07-19 |
20120183572 | Method of making microalgal-based animal foodstuff supplements, microalgal-supplemented animal foodstuffs and method of animal nutrition - The present invention is to a safe, biodegradable trace metal binding system that effectively delivers chromium, cobalt, copper, iron, manganese, molybdenum, selenium and zinc to animals. The method of preparing an animal foodstuff composition involves the steps of: providing transgenic algal cells comprising a nucleotide sequence, the nucleotide sequence being capable of expressing a non-native metal-binding protein in the transgenic algal cells; binding the metal-binding protein with at least one metal so as to produce a metal-bound adduct of the metal-binding protein; and admixing the metal-bound adduct with animal foodstuff. The invention is also to a animal foodstuff composition comprising animal foodstuff and transgenic algal cells expressing a non-native metal-binding protein in the transgenic algal cells, such that the transgenic algal cells contain the metal-binding protein and the metal-binding protein being bound to a metal. | 2012-07-19 |
20120183573 | INTRACELLULAR VIRAL VECTOR DELIVERY METHOD EMPLOYING IRON ION/VIRAL VECTOR COMPOSITE - The present invention relates to an intracellular viral vector delivery method employing an iron ion/viral vector composite. The iron ion/viral vector composite according to the present invention is not dependent on the expression of CAR and so improves the efficiency of delivery of viral vectors and gene expression in cells of diverse types, and has an outstanding virus-neutralizing antibody escape performance, exhibits little cytotoxicity and is outstandingly stable even when subjected to iron ion processing at low concentration, and hence can be used to advantage in recombinant viral vaccine compositions. | 2012-07-19 |
20120183574 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATES - The invention concerns the use of a virus for the preparation of a medicament for the vaccination or treatment of a human, wherein the virus is capable of infecting the cells of the human, but not capable of being replicated to infectious progeny virus in the human. The virus is preferably a Modified Vaccinia Virus Ankara. | 2012-07-19 |
20120183575 | EXOSOME BASED TREATMENT OF CANCER - A method of treating cancer in a patient comprises immortalizing B cells collected from the patient by infection with Epstein Barr virus, transforming the cells to a latent stage, culturing the cells in the presence of a cancer antigen, harvesting exosomes released from the cells, administering the exosomes to the patient. Alternatively the harvested exosomes are loaded with cancer antigen. | 2012-07-19 |
20120183576 | MODIFIED GRAM-NEGATIVE BACTERIA FOR USE AS VACCINES - The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host. | 2012-07-19 |
20120183577 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides processes for preparing the compounds, pharmaceutically acceptable compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders. | 2012-07-19 |
20120183578 | POLYETHYLENE GLYCOL-BASED DENDRONS - The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use. | 2012-07-19 |
20120183579 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2012-07-19 |
20120183580 | Analgesic Composition for Transbuccal Administration - The present invention relates to a pharmaceutical composition comprising a peptide of 5 to 50 amino acids which comprises the amino acid sequence NPFPTX | 2012-07-19 |